Health
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for children with OSALITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatmen
About this update from Vivos Therapeutics, Inc.
[{"type":"image","alt":"Vivos Therapeutics, Inc","displaySize":"","headline":null,"caption":"Vivos Therapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":148,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o.bVqaj5F3NG9.btjYGvyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTY1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/452f3e3cd3796a0ed8557400112a2519","width":148,"height":46}},"lazy":false},{"type":"text","content":"The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for children with OSA","length":236,"tagName":"p"},{"type":"text","content":"LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from OSA.","length":534,"tagName":"p"},{"type":"text","content":"Results from a multicenter clinical trial, now published in the European Journal of Pediatrics, represent a significant milestone in the fight against one of the most underdiagnosed and undertreated pediatric health conditions. The DNA appliance is part of Vivos’ Complete Airway Repositioning and Expansion (“C.A.R.E.”) line of devices.","length":337,"tagName":"p"},{"type":"text","content":"According to recent published research estimates, up to 20.4% of U.S. children — as many as 10 million — are living with pediatric OSA, a condition linked to ADHD behaviors, allergies, bedwetting, reduced IQ, aggressive behavior, and academic struggles. Alarmingly, up to 90% of these children remain undiagnosed. For those who are diagnosed, the current standard of care is adenotonsillectomy (AT) surgery, which is invasive, painful, and only effective for 20–40% of pediatric patients — with symptoms recurring in up to a quarter of cases.","length":542,"t...